Literature DB >> 2280177

Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.

T L Innerarity1, R W Mahley, K H Weisgraber, T P Bersot, R M Krauss, G L Vega, S M Grundy, W Friedl, J Davignon, B J McCarthy.   

Abstract

Familial defective apolipoprotein B-100 is a genetic disorder of apolipoprotein B-100 that causes moderate to severe hypercholesterolemia. A single amino acid mutation in apolipoprotein B diminishes the ability of low density lipoproteins to bind to the low density lipoprotein receptor. Low density lipoproteins accumulate in the plasma because their efficient receptor-mediated catabolism is disrupted. This mutation has been identified in the United States, Canada, and Europe and is estimated to occur at a frequency of approximately 1/500 in these populations. Thus, it appears that this newly described disorder may be a significant genetic cause of hypercholesterolemia in Western societies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280177

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  74 in total

Review 1.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.

Authors:  Daniel J Rader; Jonathan Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

2.  First International Workshop on Familial Defective apo B-100, Munich, November 1991.

Authors:  H Schuster; S Humphries; G Rauh; C Keller
Journal:  Clin Investig       Date:  1992-10

3.  Low density lipoprotein heterogeneity in spontaneously hypercholesterolemic pigs.

Authors:  S T Cooper; R J Aiello; W J Checovich; A D Attie
Journal:  Mol Cell Biochem       Date:  1992-08-18       Impact factor: 3.396

4.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

Authors:  Ingrid K Kotowski; Alexander Pertsemlidis; Amy Luke; Richard S Cooper; Gloria L Vega; Jonathan C Cohen; Helen H Hobbs
Journal:  Am J Hum Genet       Date:  2006-01-20       Impact factor: 11.025

Review 5.  Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

Authors:  Lynley M Doonan; Edward A Fisher; Jeffrey L Brodsky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-04-06       Impact factor: 4.698

6.  A versatile and tunable coating strategy allows control of nanocrystal delivery to cell types in the liver.

Authors:  David P Cormode; Gitte O Skajaa; Amanda Delshad; Nicole Parker; Peter A Jarzyna; Claudia Calcagno; Merav W Galper; Torjus Skajaa; Karen C Briley-Saebo; Heather M Bell; Ronald E Gordon; Zahi A Fayad; Savio L C Woo; Willem J M Mulder
Journal:  Bioconjug Chem       Date:  2011-03-01       Impact factor: 4.774

7.  The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins.

Authors:  S Ishibashi; J Herz; N Maeda; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

8.  Common and rare gene variants affecting plasma LDL cholesterol.

Authors:  John R Burnett; Amanda J Hooper
Journal:  Clin Biochem Rev       Date:  2008-02

9.  Familial hypercholesterolaemia: pilot study to identify children at risk.

Authors:  C J Taylor; S Olpin; J Rattenbury; A Whippey; C Lunt; N Beckles-Willson; J Higginbottom; R J Pollitt; J Bonham; L S Taitz
Journal:  J Clin Pathol       Date:  1993-08       Impact factor: 3.411

10.  Genetic variation and atherosclerosis.

Authors:  Erik Biros; Mirko Karan; Jonathan Golledge
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.